Georgia Cancer Center at Augusta University

NCI Designated Program
Georgia Cancer Center at Augusta University
Minority Based Community Clinical Oncology Program (MB-CCOP)
Augusta, Georgia

The Georgia Cancer Center Minority-Based Community Clinical Oncology Program (MB-CCOP) is designed to increase the availability of state-of-the-art cancer treatment and research to minority individuals in their own communities. Establishment of an operational base in this part of Georgia for extending cancer clinical trials and cancer prevention aims to reduce cancer incidence, morbidity, and mortality in minority populations.

The program was created by the National Cancer Institute (NCI) in 1983 and awarded to Augusta University (formerly known as Georgia Regents, the Medical College of Georgia or MCG and Georgia Health Sciences University) in August of 2004. The principal investigator is Anand P. Jillella, MD. The Grant describes the organizational and operational plans intended to provide structure for the effective implementation of multidisciplinary research. African-Americans comprise 42% of newly diagnosed cancer patients at the Georgia Cancer Center. Adult and pediatric cancer clinical trial programs at the Georgia Cancer Center have been successfully enrolling minorities to clinical trials (40% of patients entered are African-Americans). Ultimately, success of the MB-CCOP depends upon the joint efforts of three departments at the Georgia Cancer Center: Adult Hematology/Oncology, Pediatric Hematology/Oncology, and Family Medicine.

(706) 721-1660
www.gru.edu/cancer

Treatment Sites in Georgia

Clinical Trials in Georgia

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Cancer Type: Cervical Cancer

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Phase I / II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

A Randomized Phase II Trial of Nivolumab, Cabozantinib plus Nivolumab, and Cabozantinib plus Nivolumab plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC
Cancer Type: Lung Cancer, Unknown Primary

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA
Cancer Type: Kidney Cancer

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Cancer Type: Cervical Cancer

Implementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs (OaSiS)
Cancer Type: Unspecified

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Cancer Type: Breast Cancer